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PREFACE
I began my career in healthcare over twenty years ago, with the last fourteen
in the field of oncology. While I’m not a clinician, the disease is multifaceted and is
constantly evolving. Today, in 2019, we are seeing breakthroughs in which one drug
can treat different types of cancer. I foresee over the next 20 years, cancer will not
be cured, but I am confident many cancers will be managed as a chronic disease,
giving survivors not a death sentence but an opportunity to experience a fulfilled
quality of life. This has already been demonstrated in certain breast cancers as well
as prostate, colon, and lung. Patients are experiencing remission within these cancer
indications due to standard of care practices associated with annual screenings, public
health organizations promoting methods to reduce exposures to the disease, as well
as through outcomes from clinical research. When I first considered the topic for my
dissertation, I knew it would be directed in cancer. I was led to ovarian cancer by
reading the literature and hearing about patient stories, where many are diagnosed at
such a late stage. No annual or effective screening is available, and more importantly,
as the patient population is relatively small, commercializing a multi-million dollar
therapy is cost prohibitive. When I came across Dr. Goff’s research efforts associated
with symptoms and further discussed my thoughts around this project with advisors,
Drs. Krause and Cazaban, it became clear that evaluating symptoms in commercial
claims would be relevant to this field and the findings could potentially contribute to
detecting this disease at an earlier stage, receiving treatment before the cancer has
spread.
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According to the American Cancer Society, approximately twenty percent
(20% of women with ovarian cancer are diagnosed at an early stage (e.g. stage I or
II), which subsequently means eighty percent (80%) of women diagnosed with this
disease are at the late stage (e.g. stage III or IV) and are likely not to survive. No cure
exists and, concurrently, studies show mixed results in utilizing blood tests and
transvaginal ultrasounds to screen for ovarian cancer. While symptoms are not easily
discernable, some oncologists have validated there are common symptoms women
experience prior to diagnosis. As these symptoms are not routinely recognized by
general practitioners as an indicator to detect ovarian cancer, we conducted a
retrospective study to determine whether certain types of symptoms are evident prior
to the diagnosis. Our two specific aims included: (1) conduct an exploratory study to
determine if certain symptoms were prevalent in women that are diagnosed with
ovarian cancer; and (2) assess and compare symptoms experienced by women
diagnosed with ovarian cancer to women that have not been diagnosed with any type
of cancer.

The symptoms were identified by forty-seven (47) International

Classification of Disease, 9th revision (ICD-9), diagnosis codes and categorized into
four primary groups: (i) abdominal-pelvis; (ii) bladder; (iii) digestive; and (iv) pain. In
conjunction with identifying the type of symptoms experienced, reoccurrence and
combination of symptoms were also analyzed. The data to support this study was
derived from health insurance claims between 2008 through 2013 from a commercial
payer. All subjects for both studies were residents in the state of Texas and were a
minimum of 24 years old.
The analysis of the first aim of the study was primarily descriptive to assess
symptoms and frequencies experienced prior to diagnosis. Of the 3,601 women
diagnosed with ovarian cancer, 2,292 (64%) experienced a related symptom prior to
or at diagnosis. Over 60% (n=1544) of women experienced a first symptom associated
with abdomen and pelvis and 85% of overall complaints were associated with this
group of symptoms. Pain was the second most frequent complaint at 45%, followed
by digestive at 24% and bladder at 18%. This was also confirmed in women who
experienced a combination of symptoms where abdomen and pelvis along with pain
was shown to be the highest complaint at 41%.
The results of the first study consequently led to pursue the second aim which
included a nested case control study comparing a subset of 789 women diagnosed
with ovarian cancer to women who did not have any history of cancer. The results
supported statistical significance in symptoms experienced specific to abdomen and
pelvis in conjunction with pain as well as digestive.
While these symptoms are ordinary and are difficult to distinguish as having an
association with ovarian cancer, the findings of this research appear to affirm that a

symptom index may prove to be a useful method when recurring complaints are
presented in women.
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Background & Literature Review
Ovarian Cancer
Worldwide over 200,000 women are diagnosed with ovarian cancer and
125,000 die on an annual basis (Sankaranarayanan R., 2006). In the U.S., the
National Cancer Institute estimates that 22,000 new women are diagnosed with this
disease each year. Nearly 50% of the diagnosed cases occur in women under the
age of 65 and overall survival is generally less than 5 years (Ovarian Cancer, 2015).
It accounts for three percent of cancers among women (Cancer, 2015). While this
may appear to be a low figure compared to other cancer mortalities, it unfortunately
results in more deaths than any other oncologic disease of the reproductive system
(Cancer, 2015).

Ovarian cancer begins in the ovaries and is distinguished by three

different types of tumors: a) Epithelial, b) Germ Cell, and c) Stromal. Epithelial is the
most common type of ovarian cancer, representing 85%-90% of all cases (Cancer,
2015).
This cancer is recognized as an asymptomatic disease and thus is identified as
a “silent killer” (Goff B. A., 2007). Unlike other cancers, such as breast, lung, cervical,
prostate, colon or skin, no standard screening requirements to evaluate the risk of
ovarian cancer are supported by professional organizations such as The American
Congress of Obstetricians and Gynecologists or the United States Preventative
Services Task Force (USPSTF). While studies show mixed results in utilizing blood
1

test and transvaginal ultrasounds to diagnose ovarian cancer, leading gynecological
experts, such as Dr. Barbara Goff, have validated there are common symptoms
women experience prior to diagnosis. These symptoms are not recognized routinely
within clinical practice to detect ovarian cancer and subsequently this may lead to
women being misdiagnosed, causing the disease to advance to a later stage.
Continued research is necessary to further assess if recurring symptoms are shown
to have an association to ovarian cancer and, if so, whether these symptoms can be
applied as part of standard of care practice, offering earlier diagnosis, and
subsequently leading to earlier treatment and possibly long-term survival.
Symptoms of Ovarian Cancer
Ovarian cancer is difficult to diagnose and when it is discovered, many women
are at such an advanced stage of the disease that the therapy is provided for palliative
reasons. The survival rate is highly dependent on whether the cancer has spread to
other organs, the woman’s age, and response to treatment (NCI, 2015). If the disease
is confined to the ovary, also known as Stage 1 (localized), five year survival rates can
range between 70% and 90% (Cannistra, 2004; NCI, 2015).

Once the disease

advances beyond Stage I or Stage II, the average five year survival rate begins to
diminish as the cancer has either spread beyond the pelvis and has potentially
penetrated the lymph nodes (regional) or metastasized (distant) into other organs.
The National Cancer Institute’s SEER data suggests that between 2005 and 2011,
sixty percent (60%) of women are diagnosed as “distant” and a mere fifteen percent
2

(15%) are “localized” (NCI, 2015), further affirming that prognosis of this disease is
not only dismal, but also requires research to assess opportunities to detect this
disease as early as possible (Figure 1).
Figure 1: 5-Year Relative Survival
SEER 18 2005-2011, All Races, Females by SEER Summary Stage 2000

Symptom management of this disease has been limited. In the 1970s, a study
of over 5,000 women showed that most patients with ovarian cancer experienced
symptoms anywhere from two weeks to ten years prior to diagnosis (Ranney, 1979).
This research subsequently has paved the framework for Dr. Barbara Goff, an
oncological gynecologist and leading expert in ovarian cancer. Her studies in the last
10 years reveal that common targeted symptoms are evident between six and twentyfour months prior to diagnosis (Goff B. A., 2007) (Goff B. M., 2004). As a result of her
research, clinicians now are beginning to recognize common ailments in women that
require further investigation.

3

Several related symptoms addressed in Dr. Goff’s research, otherwise known
as the “symptom index” set the basis on what other investigators use as part of their
methodological framework when evaluating symptoms associated with ovarian
cancer.

The categories to support these symptoms include areas associated with

pain, eating, abdomen, bladder, bowels, menses, intercourse, and other (Goff B. M.,
2004). The symptom index is shown to be positive if one or more symptoms occur
for less than one year but for more than 12 days per month (Goff B. A., 2007).
Screening
Today, there are several types of screening tests that have shown to identify
the risk of breast, lung, cervical, prostate, colon, and skin cancer. These screening
tests are endorsed by national organizations such as the U.S. Preventive Services
Task Force, American Cancer Society, and American Society of Clinical Oncology and
are recognized as standard of care procedures by payers and clinicians. In contrast,
there are no standard of care screening methods for ovarian cancer. Over sixty
percent (60%) of ovarian cancer cases are found at Stage III and IV (Clarke-Pearson,
2009), which ultimately impacts a woman’s survival rate, as the cancer has more than
likely spread to other organs, making it very difficult to treat and place the cancer into
remission.
Should a physician detect that a woman is at risk of the disease, there are two
procedures that are initially performed prior to performing surgery to confirm
diagnosis. One is the transvaginal ultrasonography and the other is a blood test
known as a CA-125. While both procedures are noninvasive and can offer some
4

indication if a woman may or may not have ovarian cancer, the specificity and
sensitivity of these tests remain questionable on whether early detection (e.g. Stage
I) can be determined, thus potentially leading to needless surgeries (Clarke-Pearson,
2009) .
Importance of Earlier Diagnosis
While routine screening methods are not endorsed as standard of care, studies
show women that are detected at an early stage (e.g. Stage I) are able to experience
five year survival rates as high as 90%. This is primarily because the cancer has not
spread outside of the ovary. Unfortunately, though, only a small percentage of women
are diagnosed at this stage. Therapeutic options in this disease are beginning to
evolve, especially in the field of personalized medicine (i.e. use of genetic profiles in
the treatment of cancer), but effective screening, early detection, and cure remain
obscure (Rauh-Hain, 2011). For women to benefit from the chemotherapies and
simultaneously improve their survival rates, some form of early detection is needed.
Although screening tests are not routinely performed, oncologists, such as Dr. Goff,
are attempting to implement clinical decision strategies by incorporating a symptom
index that will enable physicians to possibly identify whether their patient is at risk of
the disease.

If the symptoms are evident, then further diagnostic tests can be

pursued.
Public Health Significance
Ovarian cancer remains a lethal disease world-wide.

While the overall

prevalence is much smaller compared to breast and lung cancer, the long-term
5

survival rates are one of the worst where 10-year survival is expected to be less than
50%. The main areas that influence the current state of why women are not currently
screened as well as why symptoms are not recognized as indicators in this disease
include patient awareness, the ordinariness of the symptoms, and current clinical
practice. Patient awareness is affected by the lack of information and knowledge in
recognizing that certain patterns could be associated with signs of ovarian cancer.
Target symptoms as distinguished in the literature by experts such as Dr.
Barbara Goff and others remains in question by clinicians and organizations such as
the Centers of Medicare and Medicaid, U.S. Preventative Task Force, American
Congress of Obstetricians and Gynecologists, and American Society of Clinical
Oncology. In addition to the lack of both patient awareness and understanding of
target symptoms, clinicians, in general, do not appear to be familiar with symptoms
that are evident in this field of medicine. Unless a physician is trained as an oncologist,
the primary care physician or gynecologist is generally not leaning towards cancer as
the initial diagnosis. The combination of the patient, the healthcare industry, and the
clinicians collectively not recognizing the correlation of the symptoms to ovarian
cancer may lead to delays in earlier diagnosis as well as treatment. The proposed
research objectives have the potential to contribute to a better understanding of
symptom indicators that may be associated with the disease, offering further
awareness.

6

This research is intended to explore whether symptoms are evident in women
diagnosed with this disease, and if so, how long and how frequent did the symptoms
occur prior to diagnosis.
Specific Aims
The main objective of this research is to determine if there is an association of
certain symptoms women experience prior to the diagnosis of ovarian cancer.
Outlined below are the primary research questions and related aims for this research:
Research Question 1: What are the frequencies and types of symptoms prior to
diagnosis of ovarian cancer?
Aim 1: To evaluate and compare whether certain symptoms exist prior to diagnosis
in claims data.

Primary symptoms include bloating, increased abdominal size,

abdominal pain, pelvic pain, difficulty eating, feeling full quickly and the frequency
(Andersen, 2014).
Research Question 2: What is the frequency and type of the symptoms prior to
diagnosis in comparison to an aged-matched control group of women who are not
diagnosed with cancer?
Aim 2: To determine whether women diagnosed with ovarian cancer indicate a
different frequency of target symptoms than the aged-match control group.

7
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Overview of Methods
Study Design: Both studies involved a retrospective analysis of insurance claims
over a five year period. Symptoms for both study aims were identified based on 47
International Classification of Disease (ICD-9) codes specific to pain, abdominal and
pelvis, digestive, and bladder. The first study aim (1st Journal Article) was exploratory
and descriptive, evaluating symptom complaints prior to diagnosis. The second study
aim (2nd Journal Article) supported a nested case control study, which included a
cohort of women diagnosed with ovarian cancer and were randomly matched to
women who had no history of cancer. The second aim would compare type of
symptom complaints and frequencies experienced by women with ovarian cancer to
women with no history of cancer.
Study Subjects: Subjects were identified as women diagnosed with ovarian cancer
(both studies) and women with no history of cancer (second study aim only).
Sample Size:
Study Aim 1 (1st Journal Article)
o Women diagnosed with ovarian cancer n= 3601
Study Aim 2 (2nd Journal Article)
o Women diagnosed with ovarian cancer n=789
o Women with no history of cancer n=789
o Total sample size n = 1578
Data Collection: Extraction of claims and related member files (inclusive of date of
birth) were based on: a) women diagnosed with ovarian cancer based on ICD-9
10

diagnosis codes 183.x, malignant neoplasm of ovary, and 233.39, carcinoma in situ
of the ovary), b) women with no history of cancer based on the exclusion of any history
of cancer based on ICD-9 diagnosis codes of 140.x through 239.x; and lastly c)
included all visits (claims) within the observation period.
Data Analysis: Analysis for the first study aim (1st Journal Article) was exploratory
and descriptive; Analysis for the second study aim (2st Journal Article) was descriptive
and odds ratios and p values were determined based on conditional logistic
regression.
Human Subjects, Animal Subjects, or Safety Considerations: No human or
animal subjects were involved in these studies. This study was approved by the
Institutional Review Board of The University of Texas – School of Public Health.
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Journal Article (1st)
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Are Certain Types of Symptoms Experienced Prior to the Diagnosis of Ovarian
Cancer?
AUTHORS: Denise Manon Langabeer1, Cecilia Ganduglia Cazaban2, Michael D
Swartz2, David Lopez2, and Trudy Millard Krause2
1

The University of Texas MD Anderson Cancer Center, Houston, Texas

2

The

University of Texas School of Public Health, Houston, Texas
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ABSTRACT (236 words)
Are Symptoms Experienced Prior to the Diagnosis of Ovarian Cancer? A
Retrospective Study of Insurance Claims Over a Five-Year Period
Denise Manon Langabeer, Cecilia Ganduglia Cazaban, Michael D Swartz, David
Lopez, Trudy Krause; The University of Texas MD Anderson Cancer Center,
Houston, TX; The University of Texas School of Public Health, Houston, TX
Abstract Text:
Background: The US healthcare system does not support a standard screening
method for ovarian cancer, a disease where over 60% of ovarian cancer cases are
found at a late stage. The purpose of this study is to determine whether certain types
of symptoms are evident prior to the diagnosis. Methods: A retrospective analysis
of health insurance claims between 2008 through 2013 from a commercial payer
based on the following eligibility criteria: 1) women diagnosed with ovarian cancer, 2)
at the time of diagnosis, 24 years of age or older, 3) continuously enrolled in healthcare
plan for a minimum of 6 months prior to diagnosis, and 4) a Texas resident. Symptoms
were based on 47 ICD-9 diagnosis codes and categorized specific to pain, abdominal
and pelvis, digestive, and bladder. Results: Of the 3,601 of women diagnosed with
ovarian cancer, 2,292 (64%) experienced a related symptom prior to or at diagnosis.
Over 60% (n=1380) of women experienced symptoms associated with abdomen and
pelvis. Over twelve hundred women age 30 and over 65 experienced a first symptom
greater than 90 days prior to diagnosis, with the number of unique visits ranging from
1 to 41 per woman. A combination of symptoms occurred in over 50% of women
(n=1230). Conclusions: Of the 3,601 women diagnosed with ovarian cancer, the
majority experienced symptoms prior to diagnosis. Complaints specific to abdomen
and pelvis appear to be the most common across all age groups.
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INTRODUCTION
While cancer research is producing remarkable outcomes in the field of
oncology, ovarian cancer remains a disease with short-term survival. Worldwide, over
200,000 women are diagnosed with this disease and 125,000 die on an annual basis1.
In the U.S., the National Cancer Institute estimates that over 22,000 new cases occur
annually and 14,070 women die due to this cancer2. Nearly 50% of the diagnosed
cases occur in women under the age of 65 and overall survival is generally less than
5 years3. It accounts for three percent of cancers among women4. While this statistic
may appear to be insignificant compared to other cancers, it results in more deaths
than any other oncologic disease of the reproductive system4.
Ovarian cancer is recognized as an asymptomatic disease5. The survival rate
is highly dependent on whether the cancer has spread to other organs, the woman’s
age, race, and response to treatment6. Unlike other cancers, such as breast, lung,
cervical, prostate, colon or skin, no standard screening requirements to evaluate the
potential risk are supported by professional organizations such as The American
Congress of Obstetricians and Gynecologists or the United States Preventative
Services Task Force (USPSTF). In January 2018, the Journal of American Medical
Association published USPSTF’s decision that screening for ovarian cancer in
asymptomatic women by performing a blood test, known as the cancer antigen 125
(CA-125), or the use of transvaginal ultrasounds are not beneficial, cost effective, and
do not provide opportunities for an early diagnosis7. The USPSTF has taken this
position as a result of recent research that has shown that these screening methods
15

are inconsistent leading to false positives or unremarkable findings.

This was

corroborated by the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian
(PLCO) Cancer Screening Randomized Controlled Trial, where nearly 80,000 women
were randomized to either obtain annual screening tests using both the CA-125 and
the transvaginal ultrasound or proceed with usual care. For women randomized to
annual ovarian cancer screening methods, more than 25,000 women were screened
utilizing both tests in the first three years of the study, and then subsequently with CA125 for a period of two years.

In total, 6 annual CA-125 tests and 4 annual

transvaginal ultrasounds were performed on each women involved in the study8. The
investigators of the PLCO study followed the women for over 12 years and determined
there was no statistically significant reduction in mortality in ovarian cancer between
the women that were tested annually versus women who received usual care8.
Today, innovative therapies are being offered to treat cancer in several
indications (e.g. breast, lung, skin and liver). However, it remains a challenge to direct
an effective clinical treatment to the ovarian cancer population that leads to long-term
survival. The inability to diagnose at an early stage and inadequate therapies are two
primary reasons this disease is extremely difficult to prevent or cure. Nearly 85% of
women will be diagnosed when the cancer has spread or metastasized outside of the
ovary, which sadly leads to a premature death2. A component of this research is to
continue to stimulate awareness of the possible enduring symptoms that recur in
ovarian cancer.
16

When symptoms tend to be ambiguous, time, inadvertently, is used as a
diagnostic tool. Without an effective screening strategy to determine early detection
of ovarian cancer, symptom research needs to continue and be part of a holistic
approach that is inclusive of a diagnostic pathway. Symptom research has been
monitored in this disease for several decades. In the 1970s, a study of over 5,000
women showed that most patients with ovarian cancer experienced symptoms
anywhere from two weeks to ten years prior to diagnosis9. Other later clinical research
revealed that common targeted symptoms are evident between six and twenty-four
months prior to diagnosis5, 10. Goff et al established an ovarian cancer symptom index
which has been used in several case-control studies11. The index measures whether
women experienced certain symptoms specific to pelvic/abdominal pain, difficulty
eating, urinary urgency, and bloating prior to diagnosis. The reporting of symptoms in
this disease appear to be an indicator to ovarian cancer.
This study is a retrospective analysis of healthcare claims from a large U.S.
commercial payer. The primary aim of this research is to assess whether certain
symptoms are apparent prior to the diagnosis of ovarian cancer. The research is
descriptive and will explore: a) the type of symptoms experienced, b) when the
symptoms occurred, and c) how frequently women visited their provider.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board of The University of
Texas – School of Public Health. To support the study aim, a retrospective analysis
of health insurance claims from a commercial payer between 2008 through 2013 was
17

performed. A cohort of 4,406 women diagnosed with ovarian cancer was extracted
from 3,596,696 unique women. Inclusion criteria for the analysis were the following:
a) women diagnosed with ovarian cancer (ICD-9 diagnosis codes: 183, malignant
neoplasm of ovary, and 233.39, carcinoma in situ of the ovary); b) residentially lived
in the state of Texas, c) enrolled continuously in the plan for a minimum of 6 months
prior to diagnosis, d) equal to or greater than 24 years of age at diagnosis. Of the
4,406 women diagnosed with ovarian cancer, 805 women were dropped from the
cohort due to: a) diagnosis date was outside of the continuous enrollment periods;
and b) diagnosis date before symptom date. This resulted in 3,601 women diagnosed
with ovarian cancer to be analyzed (Figure 1).
Related symptoms were identified in the claims by 47 International
Classification of Disease (ICD-9) codes specific to pain, abdominal and pelvis,
digestive, and bladder (Table 1). As the hypothesis supports a review of symptoms
prior to diagnosis, any claims that occurred subsequent to the diagnosis date were
dropped from the analysis.

Associated symptoms were analyzed by age group,

number of visits (based on claims), time period, and combination of symptoms.
The dataset for the analysis was compiled by two separate data files based on
the research criteria noted above. The first dataset comprised of enrollees who met
the demographic criteria specific to age, enrollment period, and residence. The
second dataset was based on member (n=3,601) claims specific to the cancer
diagnosis and symptoms.

Once each dataset met the specifications, the datasets

were matched based on member identification number and merged.
18

The statistical package used for the analysis was STATA 13.1. This research
primarily reports descriptive analyses and includes the following: i) proportions of the
number of women that experienced a visit with symptoms versus no symptoms, ii) the
type of first symptoms experienced prior to diagnosis, iii) the number of days the first
symptom occurred prior to diagnosis, iv) combination of symptoms experienced, and
v) the range of recurring visits by symptom and age.
RESULTS
There were 3,601 women included in the analysis that met the study criteria.
Women ranged in age from 24 through 89, with an average age of 53 (SD 12.20). Of
the 3,601 women, symptoms prior to the diagnosis were found in 64% (n=2292)
(Figure 2). Of the women that experienced symptoms prior to diagnosis, 32% (n=731)
were between the age of 50 and 59. The analysis further revealed that 60% of women
treated for their first symptom primarily presented with a complaint associated with
abdomen and pelvis. The second most frequent complaint as a first symptom was
associated with pain (16%), followed by digestive (13%), and bladder (11%) (Figure
3).
Of the 2,292 women with symptoms, time and the number of visits was
reviewed. The following results are described in figures 4 through 6. To understand
the time between first symptom and diagnosis, the researchers performed an analysis
on the number of days the initial symptom occurred prior to the diagnosis. Women
that experienced a symptom on the day of diagnosis were removed from the analysis
and further analysis occurred on symptoms that ranged between 1 to greater than 365
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days. Of the 2,292 women, 46% (n=1063) experienced a first symptom under 90 days
prior to diagnosis. Women in this analysis from age 30 to over 65 (n=739; 32%) had
a first symptom visit over a year prior to diagnosis.
In conjunction with determining the number of days of the first symptom prior
to diagnosis, the number of symptom visits by each of the 2,292 women was analyzed.
A total of 10,970 visits (correlated with date of service) across all age groups were
evaluated. Eighty-five percent (85%; n=1954) complained of symptoms associated
with abdomen and pelvis with over 1,400 women experiencing more than one visit.
Complaints associated with pain effected forty-five percent (45%; n=1031) of women,
with digestive following at 24%, and bladder at 18% (Figure 4).

Plot graphs were

created to show the distribution of visits for each category of symptoms by number of
women. Nearly 500 women experiencing symptoms for abdomen and pelvis went to
their physician five or more times. Four women had over 30 recurring visits in this
symptom (Figure 5). Each of the other category of symptoms also displayed a range
of recurring visits. Over 100 women had five or more recurring visits associated with
digestive, with one experiencing forty-one (41) visits (Figure 6). In regards to bladder,
these symptoms appear to be less frequent than the other symptoms, however, 138
women did experience between two to eighteen recurring visits (Figure 7). Lastly,
symptoms associated with pain ranged between 2 visits to 41, with seventy-two
women experiencing five or greater (Figure 8).
Another segment to the analysis involved whether women may have
experienced a combination of symptoms.

Of the 2,292 women, 54% (n=1,230)
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experienced a combination of symptoms prior to diagnosis. A total of ten different
combinations were analyzed. The results showed that 41% experienced symptoms
associated with pain along with abdomen and pelvis, and 17% experienced digestive
with abdomen and pelvis (Figure 9; Table 2).

Combination of symptoms were

experienced in all age groups, with 53% in women aged 40 to 59.
DISCUSSION
This research remains relevant as ovarian cancer continues to be recognized
as a disease where long-term survival statistics are dismal. Currently, the female
gender comprises of nearly 50% of the world population and life expectancy is
expected to grow as a result of public health advances, which in turn is also projected
to lead to an increase of cancers cases of nearly 10 million with 5.5 million deaths by
203012. Agencies such as the National Cancer Institute, American Cancer Society,
and other noteworthy coalitions assert that 50% of ovarian cancer cases occur under
the age of 65, with the median age of 63. This statistic was further supported by the
commercial claims data used for this research, where 80% of the 3,601 women
diagnosed with this disease were between the ages of 30 through 64 (n=2895). This
research shows that pre-existing symptoms, especially specific to abdomen and
pelvis, appear to exist prior to diagnosis. Of the initial 3,601 women, 64% experienced
a related symptom prior to or on the day of diagnosis. Further analysis of the 2,292
women that experienced a symptom, 54% (n=1233) had a first visit between 91 days
to over a year prior to diagnosis. The frequency of symptom visits ranged from 1 to
more than 40 visits.
21

The investigators recognize that this type of prescreening assessment cannot
independently lead to a diagnosis of ovarian cancer.

However, this study does

strongly suggest that a taxonomy of symptoms is beneficial as a prescreening
approach prior to pursuing tests, such as a CA125 or transvaginal, which can be
expensive and also lead to false positives13. With most hospitals both in the U.S. and
abroad utilizing sophisticated electronic health records and big data analytics (e.g.
IBM Watson), evaluation of symptoms in combination with a thorough risk assessment
could lead to opportunities for better clinical decisions as well as offering earlier
interventions.

While not extensively shown in ovarian cancer thus far, there is

research that is demonstrating impactful results in other areas. For example, in
diabetic retinopathy, the investigators applied a clinical decision support system
(CDSS) in conjunction with a lab data and patient demographics to detect
susceptibility to diabetic retinopathy (DR) with high accuracy14. Similar to ovarian
cancer, detection of DR is asymptomatic and requires specialized physicians (i.e.
ophthalmologists) and expensive tests to assess the risk. The researchers of the
study were able to develop a predictive clinical application that could accurately detect
DR at 93% based on a routine blood test14.
Limitations and Strengths
Insurance claims were historically developed for the purpose to support
physician documentation and charge reimbursement, which for purposes of research,
such as the one presented, has limitations. For example, for this study, detailed
clinical information about the disease, demographics, and stage of the disease are not
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captured in the claims data. Additionally, the claims associated with this study are
from a commercial payer, which eliminates any data from women who may be on
primary healthcare plans associated with the Centers for Medicare and Medicaid
Services.

This limits extrapolation of our findings to other populations such as

uninsured and lower income women as well as women over the age of 65.
Apart from the limitations of the analysis, this research exhibits strengths. The
database used for this study has over 3.5 million women members in the state of
Texas, and enabled the investigators to analyze age, time of symptoms to diagnosis,
number of visits specific to related symptoms, as well as combination of symptoms
without recall bias. Another advantage of using claims data is the ability to evaluate
visits across multiple providers.
CONCLUSIONS
Patients routinely experiencing a type of symptom epidemiology want to be
referred and diagnosed expeditiously15. While meaningful advancements continue to
rapidly evolve in diagnostics and genetic testing, ovarian cancer still remains without
any type of standard screening method along with limited treatment options. It is
inferred that early detection increases the chances for long-term survival.

This

research supported that over 64% women experienced a related symptom, with the
majority experiencing recurring symptoms.
Incorporating a symptomology index as part of the clinical diagnostic strategy
may lead to earlier detection16. Although the results were not statistically significant,
a recent United Kingdom Collaborative Trial of Ovarian Cancer Screening revealed a
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15% reduction in ovarian cancer mortality with multimodal screening which included
a CA125 based risk of ovarian cancer algorithm (known as ROCA) followed by
transvaginal ultrasound, if the ROCA was abnormal17. Based on the outcomes of our
exploratory retrospective analysis as well as other studies, including prospective
clinical studies such as those supported by Dr. Goff, it does appear that more
awareness needs to be directed to women and health care providers. In the United
States, the National Cancer Institute is disclosing some early results of a NCI-funded
study of an experimental pap screening test.

The retrospective study detected

endometrial and ovarian cancer through DNA collected from blood and tissue2.
Further research needs to continue, both within the U.S. and globally, to not only
validate the efficacy of symptoms related to ovarian cancer, but also whether recurring
symptoms are red flags to subsequently promote diagnostic testing whether through
traditional methods (i.e. CA-125 blood test, transvaginal ultrasound) or more
advanced methods such as molecular pathways evaluating the cytology of the human
cells.
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Figure 1 Study Design
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Table 1 Symptoms Categorized by ICD9 Diagnosis Codes (47 codes
Category
Pain

Abdomen &
Pelvis

Digestive

Bladder

ICD9
6250
6255
6258
6259
7245

Description
Dyspareunia
Pelvic congestion syndrome
Other specified symptoms associated with female genital organs
Unspecified specified symptoms associated with female genital organs
Backache

5340
5781
6262
6266
6267
6268
6269
7890
78900
78901
78902
78903
78904
78905
78906
78907
78909
7893
78930
78935
78936
78959
7896
78965

Gastritis
Blood in stool
Excessive or frequent menstruation
Metrorrhagia; bleeding unrelated to menstrual cycle; irregular intermenstrual bleeding
Postcoital bleeding; bleeding from vagina after sexual intercourse
Dysfunctional or functional uterine hemorrhage
Disorders of menstruation & other abnormal bleeding from female genital tract; unspecified
Abdominal pain
Abdominal pain; unspecified
Abdominal pain; right upper quadrant
Abdominal pain; left upper quadrant
Abdominal pain; right lower quadrant
Abdominal pain; left lower quadrant
Abdominal pain; periumbilic
Abdominal pain; epigastric
Abdominal pain; generalized
Abdominal pain; other specified site
Abdominal or pelvic swelling, mass or lump
Abdominal or pelvic swelling, mass or lump; unspecified
Abdominal or pelvic swelling, mass or lump; periumbilic
Abdominal or pelvic swelling, mass or lump; epigastric
Ascites ‐ fluid in peritoneal cavity; other specified site
Abdominal tenderness
Abdominal tenderness; periumbilic

78966
78960
7899
5361
5369
7830
7831
7832
7873
7879
78791
7880
7881
7883
78840
78841
78842
78843

Abdominal tenderness; epigastric
Abdominal tenderness; unspecified
Other symptoms involving abdomen and pelvis
Acute dilatation of stomach
Unspecified functional disorder of stomach
Anorexia (loss of appetite)
Abnormal weight gain
Abnormal weight loss
Flatulence, eructation & gas pain
Other symptoms involving digestive system
Diarrhea
Renal colic
Dysuria
Urinary incontinence
Frequency of urination & polyuria
Urinary frequency
Polyuria
Nocturia
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Figure 2 Women with Symptoms and No Symptoms
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Figure 3 First Symptoms
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Figure 4 Number of Women Experiencing Recurring Symptoms
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Figure 5 Frequency of Visits by Women for Each Symptom (Abdomen and
Pelvis)
Frequency of Abdomen and Pelvis Symptoms
Visits Women
0
338 ********************************
1
554 *****************************************************
2
421 ****************************************
3
290 ****************************
4
196 *******************
5
146 **************
6
109 **********
7
67 ******
8
42 ****
9
33 ***
10
18 **
11
16 **
12
13 *
13
15 *
14
5
15
6 *
85% of women had abdom & pelvis symptoms
16
3
17
3
18
1
19
1
20
2
21
2
22
2
23
3
27
1
29
1
31
1
32
1
35
1
38
1
Total
2,292
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Figure 6 Frequency of Visits by Women for Each Symptom (Digestive)
Frequency of Digestive Symptoms
Visits Women
0
1739 *****************************************************
1
316 **********
2
117 ****
3
46 *
4
36 *
5
7
6
9
7
4
8
4
9
3
24% of women had digestive symptoms
10
1
12
2
13
2
14
1
16
1
19
1
20
1
21
1
41
1
Total
2292
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Figure 7 Frequency of Visits by Women for Each Symptom (Bladder)
Frequency of Bladder Symptoms
Visits Women
0
1885 *****************************************************
1
269 ********
2
71 **
3
28 *
4
17
5
8
6
3
18% of women had bladder symptoms
7
3
8
1
9
1
11
2
12
1
14
1
18
2
Total
2292
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Figure 8 Frequency of Visits by Women for Each Symptom (Pain)

Frequency of Pain Symptoms
Visits Women
0
1,261 *****************************************************
1
589 *************************
2
226 *********
3
100 ****
4
44 **
5
23 *
6
14 *
7
14 *
45% of women had pain symptoms
8
5
9
4
10
3
11
1`
12
2
17
1
22
1
23
2
31
2
Total
2,292
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Figure 9 Combination of Symptoms Experienced By Visits & Age
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Table 2 Combination of Symptoms Experienced By Visits & Age
Age Group
Symptom
Combination
by Age
AbP+B
AbP+B+D
AbP+B+D+P
AbP+D
D+B
P+AbP
P+AbP+B
P+AbP+D
P+B
P+D
Grand Total
%

20
0
0
0
2
0

30
11
2
5
8
1

40
20
5
12
47
2

50
32
9
17
53
6

60
22
7
9
44
2

65
20
7
14
54
3

24
5
3
1
1
36
3%

92
13
29
4
0
165
13%

112
37
41
4
3
283
23%

166
33
44
5
7
372
30%

46
14
14
3
2
163
13%

62
17
25
8
1
211
17%

Grand
% by
Total
Symptom
105
9%
30
2%
57
5%
208
17%
14
1%
502
119
156
25
14
1230
100%

41%
10%
13%
2%
1%
100%

Legend:
AbP+B

Abdomen and Pelvis + Bladder

AbP+B+D

Abdomen and Pelvis + Bladder + Digestive

AbP+B+D+P Abdomen and Pelvis + Bladder + Digestive + Pain
AbP+D

Abdomen and Pelvis + Digestive

D+B

Digestive + Bladder

P+AbP

Pain + Abdomen and Pelvis

P+AbP+B

Pain + Abdomen and Pelvis + Bladder

P+AbP+D

Pain + Abdomen and Pelvis + Digestive

P+B

Pain + Bladder

P+D

Pain + Digestive
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ABSTRACT (401 words)
Are Symptoms Distinguishable in Ovarian Cancer? A Nested Case Control
Study of Insurance Claims
Denise Manon Langabeer, Cecilia Ganduglia Cazaban, Michael D Swartz, David
Lopez, Trudy Millard Krause; The University of Texas MD Anderson Cancer Center,
Houston, TX; The University of Texas School of Public Health, Houston, TX
Abstract Text:
Background: Over 60% of ovarian cancer cases are found at Stage III and IV. The
US healthcare system does not support a standard screening method for ovarian
cancer. The purpose of this study is to determine whether certain types of symptoms
are distinguishable between women diagnosed with ovarian cancer and women
without cancer. Methods: Women diagnosed with ovarian cancer were randomly
matched 1:1 to women without cancer to support a nested case-control analysis of
health insurance claims between 2008 through 2013 from a commercial payer. The
following eligibility criteria was applied: 1) 24 years of age or older; 2) continuously
enrolled in healthcare plan for a minimum period of 6 months; 3) experienced more
than 1 symptom over the observation period; 4) an observation period of a minimum
of 6 months; and 5) a Texas resident. Symptoms were based on 47 ICD-9 diagnosis
codes and categorized specific to pain, abdominal and pelvis, digestive, and bladder.
A total of 1,578 women (789 cases; 789 controls) supported the analysis. Results:
Sixty percent (60%) of women with ovarian cancer experienced the majority of
associated pre-diagnosed symptoms analyzed for the study. Visits occurred over a
period of 6 months to 70 months. Overall, ninety percent (90%; n=1,421) of the
symptoms were experienced in abdomen and pelvis, with women with ovarian cancer
visiting their physician for this complaint at 92% (n=725); OR of 1.66 (CI 1.14 to 2.41;
P=.008). Pain was reported as a complaint by cases at nearly 60% (n=464) and
controls at 48% (n=376); OR of 1.75 (CI 1.39 to 2.19; P<.001). Symptoms for bladder
and digestive combined represented 68% of complaints for both cases (n=507) and
controls (n=555), with results supporting no statistical significance to women
diagnosed with ovarian cancer. Of the 1,578 women, 77% (cases=621; controls=595)
experienced more than one type of symptom. Both cases (n=206) and controls
(n=153) complained of both abdomen and pelvis along with pain; OR of 1.54 (CI 1.19
to 1.99; P=.001). A second combination including abdomen and pelvis with pain and
digestive was experienced in 14% of women (cases n=99; controls n=67); OR 1.58;
CI 1.13 to 2.22; P=.008. Conclusions: Certain recurring symptoms associated with
abdomen and pelvis as well as pain appear to have indication of exposure to ovarian
cancer, signifying that symptom awareness remains relevant to this disease that is
diagnosed at a late stage and currently does not have routine screening methods to
support early detection.
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INTRODUCTION
According to the Centers for Disease Control and Prevention (CDC), average
life expectancy for women in the US has risen from 70 years old in 1980 to 80.1 in
2015. Preventive healthcare screenings and innovative therapies are contributing to
longer survival. This is evident in certain cancers, such as breast and lung, where the
United States Preventative Services Task Force (USPSTF) recommends annual
mammograms and low-dose CT scans to detect signs of breast or lung cancer,
respectively. Early detection along with choices in therapies have offered women the
ability to go into remission for many years. This is not the case, however, for ovarian
cancer, which accounts for 4% of all cancers in women1. Worldwide, over 200,000
women are diagnosed with this disease and 125,000 die on an annual basis2. In the
U.S., the National Cancer Institute estimates that over 22,240 new cases occur
annually and 14,070 women die from this cancer3. Nearly 50% of the diagnosed cases
occur in women under the age of 65 and overall survival is generally less than 5
years4. The survival rate is highly dependent on whether the cancer has spread to
other organs, the woman’s age, race, and response to treatment4.
Standard screening requirements to evaluate the potential risk are not
supported by professional organizations such as The American Congress of
Obstetricians and Gynecologists or the United States Preventative Services Task
Force. In 2018, The Journal of American Medical Association published USPSTF’s
position that screenings for ovarian cancer in asymptomatic women with a blood test,
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known as the cancer antigen 125 (CA-125), or transvaginal ultrasound are not
beneficial, cost effective, and do not provide opportunities for an early diagnosis5. The
USPSTF has taken this position as a result of recent research that showed that these
screening methods are inconsistent, leading to false positives or unremarkable
findings. This was corroborated by the National Cancer Institute’s Prostate, Lung,
Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial,
where nearly 80,000 women were randomized to either obtain annual screening tests
using both the CA-125 and the transvaginal ultrasound or proceed with usual care.
For women randomized to annual ovarian cancer screening methods, more than
25,000 women were screened utilizing both tests in the first three years of the study,
and then subsequently with CA-125 for a period of two years. In total, 6 annual CA125 tests and 4 annual transvaginal ultrasounds were performed on each women
involved in the study6. The investigators of the PLCO study followed the women for
over 12 years and determined there was no statistically significant reduction in
mortality in ovarian cancer between the women that were tested annually versus
women who received usual care6.
While clinical research in ovarian cancer is occurring, it remains a challenge to
direct an effective treatment that leads to long-term survival. The inability to diagnose
at an early stage and inadequate therapies are two primary reasons this disease is
extremely difficult to diagnose or, subsequently, cure. Nearly 85% of women will be
diagnosed when the cancer has spread or metastasized outside of the ovary, which
leads to a premature death3.
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The primary objective of this research is to continue to draw awareness to this
disease and to assess whether certain symptoms are able to predict signs of ovarian
cancer.

Symptom related research has been monitored in this disease for several

decades. In the 1970s, a study of over 5,000 women showed that most patients with
ovarian cancer experienced symptoms anywhere from two weeks to ten years prior to
diagnosis7. Other more recent research revealed that common targeted symptoms are
evident between six and twenty-four months prior to diagnosis utilizing an ovarian
cancer symptom index8,9. The index measures whether women experienced certain
symptoms specific to pelvic/abdominal pain, difficulty eating, urinary urgency, and
bloating prior to diagnosis.
In general, ovarian cancer is perceived as having no disease specific
symptoms8. Women have a tendency to ignore common symptoms and attribute them
to ageing, weight gain or other natural physiological processes10. This lack of
recognition contributes to a delay in seeking medical attention10 and subsequently to
a late presentation where the disease has metastasized within the lower abdomen11.
Continuing to perform research to assess if symptoms in this disease are prevalent
remains critical for both women as well as clinicians. Evidence-based symptomology
of this disease may, at a minimum, provide earlier detection.
This study is a nested case-control analysis of healthcare claims from a large
U.S. commercial payer. The primary aim of this research is to assess whether certain
symptoms are distinguishable between women diagnosed with ovarian cancer and
women who did not develop cancer. The research will explore a relationship between
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the types of symptoms experienced as well as the frequency of recurring symptoms
in women with ovarian cancer in comparison to women with no history of cancer.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board of The University of
Texas – School of Public Health.
Database Description
The data and analysis for this case-control study was based on health claims
data from a large U.S. commercial payer that provides health care coverage to over
100 million people. The insurance database and related medical claims were able to
support demographic eligibility and study criteria.
Case‐Control Study Design
The rationale for this study is to evaluate how associated symptoms compare
between women with ovarian cancer (case) to women with no history of cancer
(control).

The analysis supported visits that occurred between January 1, 2008

through December 31, 2013. Symptoms were identified in both case and control
groups by reported claims identified by 47 International Classification of Disease (ICD9) codes specific to pain, abdominal and pelvis, digestive, and bladder (Table 1). All
related symptoms were categorized and analyzed within one of the four symptom
groups. Specific to ovarian cancer cases, a review of symptoms prior to diagnosis
only occurred.

Any claims that occurred subsequent to the diagnosis date were
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dropped from the analysis. Symptom visits for controls occurred over the continuous
enrollment period.
The women diagnosed with ovarian cancer (case group) comprised of an initial
cohort of 4,406 from 3,596,696 unique women. Inclusion criteria for the analysis were
based on the following: a) women diagnosed with ovarian cancer (ICD-9 diagnosis
codes: 183, malignant neoplasm of ovary, and 233.39, carcinoma in situ of the ovary);
b) Texas resident; c) a minimum of 6 months of continuous enrollment in the plan; e)
equal to or greater than 24 years of age at diagnosis; and f) experienced a related
symptom documented by a specific ICD-9 code. Of the 4,406 women diagnosed with
ovarian cancer, 2,308 were dropped due to enrollment periods occurring either prior
to January 1, 2008 or subsequent to December 31, 2013, symptoms were identified
either on or subsequent to diagnosis date, did not meet the six-month minimum
continuous enrollment period prior to diagnosis, did not have an consecutive
observation period of a minimum of 180 days, or experience a minimum of two
symptoms over the course of the observation period. An additional 1,309 were
dropped as no related symptoms were reported prior to diagnosis. This resulted in
789 women diagnosed with ovarian cancer to be matched 1:1 with women with no
history of claims associated with cancer.
The control cohort was extracted from the claims database based on the same
criteria as the cases with the exception of a cancer diagnosis. Women with history of
any type of cancer based on the International Classification of Disease (ICD-9) codes
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140.x through 239.x were exempt from the control group.

This resulted in 317,748

controls.
The match was randomly based on the following criteria of each of the 789
cases: a) age at first symptom; b) first symptom experienced; and c) observation
period. If a control duplicated to a case based on criteria, a subsequent control with
the same criteria was selected. At complete dataset of 1578 (789 cases/789 controls)
was created for the analysis. A pair identifier was created to associate a case to
control based on the match criteria. This group variable along with a dependent
variable supporting women with ovarian cancer (case) or without cancer (control) was
applied to the conditional logistic regression when determining the association of
symptoms between cases and controls.
This research reports descriptive analyses as well as estimates of odds ratios
(OR) with 95% confidence intervals (95%, CI) and statistical significance for the
following: i) comparison of type of symptoms in cases and controls, ii) comparison of
combination of symptoms experienced, and iii) a summary of visits and observation
periods in each category of symptoms specific to cases and controls. The statistical
package used for the analysis was STATA 13.1.
RESULTS
The total number of women included in the analysis that met the study criteria
and matched was 1,578 (case: 789 / control: 789). Women ranged in age from 24 to
86, with an average age of 51 (SD 12.3065). Four hundred and eighty six women
(n=486/1578; 31%) between the age of 50 and 59 represented the largest group of
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women in the case control cohort. The analysis further revealed that 54% of women
had a first symptom primarily presented with a complaint associated with abdomen
and pelvis. The second most frequent complaint was associated with pain (17%),
followed by digestive (15%) and bladder (14%). The observation period ranged from
6 months to 70 months. (Table 2).
Women in both cases and controls experienced multiple symptoms throughout
the respective observation period. Both individual and combination of symptoms were
constructed and analyzed based on the four primary symptom categories of abdomen
and pelvis, bladder, digestive and pain. Women in both groups (n=1578) could
experience multiple visits associated with one symptom or across multiple symptoms.
Overall, ninety percent (90%; n=1,421) of the symptoms were experienced in
abdomen and pelvis, with women with ovarian cancer visiting their physician for this
complaint at 92% (n=725) and women without cancer at 88% (n=696) (Table 3). This
particular group of symptoms produced an OR of 1.66 (CI 1.14 to 2.41; P=.008),
indicating that recurring symptoms of abdomen and pelvis may be a predictive
indicator of ovarian cancer compared to women without cancer. Following abdomen
and pelvis were symptoms associated with pain at 53% (n=840). Cases (59%; n=464)
had reported nearly 10% more complaints than controls (48%; n= 376). Results for
pain appear to also show an association to risk of ovarian cancer with an OR of 1.75
(CI 1.39 to 2.19; P<.001). Symptoms for bladder and digestive combined represented
approximately 68% of complaints for both cases (n=507) and controls (n=555). These
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latter symptoms did not support they were predictive symptoms to the diagnosis of
ovarian cancer with an odds ratio of .72 and .87, respectively (Table 3).
Of the 1,578 women, 77% (cases=621; controls=595) experienced more than
one type of symptom. In reviewing ten combinations of symptoms, 30% experienced
symptoms associated with pain along with abdomen and pelvis, and 17% experienced
digestive with abdomen and pelvis (Table 4). Odds ratios and related confidence
intervals support that a certain combination of symptoms experienced in women prior
to diagnosis may be discernable in comparison to women without cancer. Compared
to the analysis of the individual symptoms, 33% (n= 206) of women with ovarian
cancer and 30% (n=153) of women without cancer complained of both abdomen and
pelvis along with pain. The OR produced a result of 1.54 (P=.001) revealing that the
odds of symptom complaints for women with ovarian cancer to women without cancer
were significant, possibly demonstrating an associated risk to the disease. This also
applied to symptoms which, again, include abdomen and pelvis, along with pain, and
digestive (OR 1.58; CI 1.13 to 2.22; P=.008).
Total number of symptom visits reported within the respective observation
months were evaluated in both cases and controls for each category of symptoms.
The number of total visits equaled 13,126, with cases experiencing 60% (n=7890) of
the visits. The average number of visits for controls equaled 6.63 (SD 5.27) and 10 for
cases (SD 7.79). The average age of women experiencing symptoms during the 40
months of observation ranged between 49 and 53.

Visits occurred over an

observation period between six months to seventy months. The analysis of each of
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the category (digestive, bladder, pain and abdomen and pelvis) of symptoms showed
that women with ovarian cancer had an average of more symptom visits per woman
(Figures 1 through 4). Additionally, a review of symptoms occurred between 6 months
to 40 months (3.33 years), which demonstrated that over 70% of symptoms during
this period occurred prior to diagnosis on 80% of the women with ovarian cancer.
Comparatively, women diagnosed with ovarian cancer appear to experience, on
average, an increase of number of visits associated with all symptoms than women
without cancer.
DISCUSSION
Ovarian cancer continues to be recognized as a disease where long-term
survival statistics are dismal. Currently, the female gender comprises nearly 50% of
the world population and life expectancy is expected to grow as a result of public
health advances, which in turn is also projected to lead to an increase of cancer cases
of nearly 10 million with 5.5 million deaths by 203012. Agencies such as the National
Cancer Institute, American Cancer Society, and other noteworthy coalitions assert that
50% of ovarian cancer cases occur under the age of 65, with the median age of 63.
The primary objective of this research was to determine a correlation of symptoms
experienced in women diagnosed with ovarian cancer to women who do not develop
cancer through a nested case control analysis. The results of the research found that
women diagnosed with ovarian cancer experienced 20% more symptom visits in
comparison to women without cancer and the association was statistically significant
in complaints associated with abdomen and pelvis along with pain.
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The investigators recognize that this type of prescreening assessment cannot
independently lead to a diagnosis of ovarian cancer.

However, this study does

strongly suggest that a taxonomy of symptoms remains beneficial as a prescreening
approach prior to pursuing tests, such as a CA125 or transvaginal, which can be
expensive and also lead to false positives13. Evaluation of symptoms in combination
with a thorough risk assessment could lead to opportunities for better clinical decisions
as well as offer earlier interventions.

Additionally, while not part of this research, it

would be of interest to possibly reevaluate a portion of the controls on this study who
experienced recurring symptoms and assess if a diagnosis of ovarian cancer was
eventually determined. The majority of women in this study were fifty and over which
links to when the highest rates of diagnosis occur for this disease.
Limitations and Strengths
Insurance claims were historically developed for the purpose to support
physician documentation and charge reimbursement, which for purposes of research,
such as the one presented, has limitations. For example, for this study, detailed
clinical information about the disease, demographics, and stage of the disease are not
captured in the claims data. Additionally, the claims associated with this study are
from a commercial payer, which eliminates any data from women who may be on
primary healthcare plans associated with the Centers for Medicare and Medicaid
Services.

This limits extrapolation of our findings to other populations such as

uninsured and lower income women as well as women over the age of 65.

An

additional limitation is that certain symptoms are subjective. For example, the
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researchers recognize that pain was restricted to five (5) ICD-9 codes – dyspareunia,
pelvic congestion syndrome, other to female genital organs, unspecified to female
genital organs, and backache. The five types of symptom complaints were included
based on prior research related to the symptomology of ovarian cancer. Future
research in this area may need to expand the symptoms of pain and better define the
type of pain experienced in order to better understand the association to ovarian
cancer.
Apart from the limitations of the analysis, this research exhibits strengths. The
database used for this study has over 3.5 million women members in the state of
Texas, and enabled the investigators to analyze age, time of symptoms to diagnosis,
number of visits specific to related symptoms, as well as combination of symptoms
without recall bias. Another advantage of using claims data is the ability to evaluate
visits across multiple providers.
CONCLUSIONS
Patients routinely experiencing a type of symptom epidemiology want to be
referred and diagnosed expeditiously14. While meaningful advancements continue to
rapidly evolve in diagnostics, genetic testing, and therapies, ovarian cancer still
remains without any type of standard screening method along with limited treatment
options. As with many cancer diagnoses, the assumption is that the earlier the
disease is detected, the chances for long-term survival increase. Educating women
and health care providers about related symptoms needs to be part of the diagnostic
strategy to increase early detection15. This was recognized in the United Kingdom
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Collaborative Trial of Ovarian Cancer Screening trial. Although the outcome was not
statistically significant,

the study did reveal a 15% reduction in ovarian cancer

mortality with multimodal screening which includes a CA125 – based risk of ovarian
cancer algorithm (known as ROCA) followed by transvaginal ultrasound, if the ROCA
was abnormal16.
In the United States, the National Cancer Institute is disclosing some early
results of a NCI-funded study of an experimental pap screening test.

The

retrospective study detected endometrial and ovarian cancer through DNA collected
from blood and tissue3. Further research needs to continue, both within the U.S. and
globally, to not only validate the efficacy of symptoms related to ovarian cancer, but
also whether recurring symptoms are red flags to subsequently promote diagnostic
testing through traditional methods (i.e. CA-125 blood test, transvaginal ultrasound)
or more advanced methods such as molecular pathways evaluating the cytology of
the human cells. A recent prospective study conducted at the Seattle Cancer Care
Alliance and the University of Washington incorporated both a symptom assessment
and a biomarker marker test to predict ovarian cancer in women with adnexal mass17.
Women were initially interviewed prior to surgery regarding their symptoms.
Symptoms that were shown to recur greater than 12 times in a one month period and
were present for less than one year would be considered eligible to participate in the
biomarker collection17. The results of the study determined that incorporating both
methods was effective in determining the risk of the disease and has the potential to
improve patient outcomes.
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The intent of this research is not to cause alarm, but to continue the awareness
of symptoms associated of ovarian cancer and direct recurring symptoms of this
disease into an integrative screening method that will lead to earlier referrals to
gynecologic oncologists, that in turn, provide earlier diagnosis, which is considered
essential in a disease that has dismal outcomes.

56

ACKNOWLEDGMENTS OF RESEARCH SUPPORT FOR THE STUDY: This work
was made possible through The University of Texas School of Public Health’s Center
for Healthcare Research Data. No funding was provided to support this study.

57

AUTHOR DISCLOSURE STATEMENT: None of the authors have received support
for the study and no competing financial interest exits. The data used for this analysis
was provided by a commercial payer that has a formal contractual relationship with
The University of Texas – School of Public Health with the intent to further healthcare
research, such as the one presented.

58

REFERENCES
1. Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in
primary care: Population based case-control study. BMJ. 2009;339:b2998.
2. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: The size of the
problem. Best Practice & Research Clinical Obstetrics & Gynaecology. 2006;20(2):207-225.
3. National Cancer Institute. www.cancer.gov. Updated Retrieved March 31, 2019.
4. American Society of Clinical Oncology. www.asco.org. Updated Retrieved March 31, 2019.
5. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for ovarian cancer:
US preventive services task force recommendation statement. JAMA. 2018;319(6):588-594.
6. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: The prostate,
lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA.
2011;305(22):2295-2303.
7. Ranney B, Ahmad M. Early identification, differentiation and treatment of ovarian neoplasia.
International Journal of Gynecology & Obstetrics. 1979;17(3):209-218.
8. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index.
Cancer. 2007;109(2):221-227.
9. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in
women presenting to primary care clinics. JAMA. 2004;291(22):2705-2712.
10. Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: A
qualitative and quantitative study. BJOG. 2008;115(8):1008-1014.
11. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet.
2014;384(9951):1376-1388.
12. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: Burden and trends.
Cancer Epidemiology Biomarkers & Prevention. 2017:cebp.0858.2016.
13. Devlin SM, Diehr PH, Andersen MR, Goff BA, Tyree PT, Lafferty WE. Identification of ovarian
cancer symptoms in health insurance claims data. Journal of Women's Health. 2010;19(3):381-389.
14. Vedsted P, Olesen F. A differentiated approach to referrals from general practice to support early
cancer diagnosis - the danish three-legged strategy. Br J Cancer. 2015;112 Suppl 1:S65-9.
15. Cooper CP, Gelb CA, Trivers KF, Stewart SL. Intended care seeking for ovarian cancer
symptoms among U.S. women. Preventive Medicine Reports. 2016;3:234-237.
16. Berchuck A, Havrilesky LJ, Kauff ND. Is there a role for ovarian cancer screening in high-risk
women? JCO. 2017;35(13):1384-1386.

59

17. Urban RR, Pappas TC, Bullock RG, et al. Combined symptom index and second-generation
multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass. Gynecol
Oncol. 2018;150(2):318-323.

60

TABLES; ILLUSTRATIONS/FIGURES; UNITS OF MEASUREMENT;
ABBREVIATONS AND SYMBOLS

61

Table 1: Symptoms Categorized by ICD9 Diagnosis Codes (47 codes)
Category
Pain

Abdomen &
Pelvis

Digestive

Bladder

ICD9
6250
6255
6258
6259
7245

Description
Dyspareunia
Pelvic congestion syndrome
Other specified symptoms associated with female genital organs
Unspecified specified symptoms associated with female genital organs
Backache

5340
5781
6262
6266
6267
6268
6269
7890
78900
78901
78902
78903
78904
78905
78906
78907
78909
7893
78930
78935
78936
78959
7896
78965

Gastritis
Blood in stool
Excessive or frequent menstruation
Metrorrhagia; bleeding unrelated to menstrual cycle; irregular intermenstrual bleeding
Postcoital bleeding; bleeding from vagina after sexual intercourse
Dysfunctional or functional uterine hemorrhage
Disorders of menstruation & other abnormal bleeding from female genital tract; unspecified
Abdominal pain
Abdominal pain; unspecified
Abdominal pain; right upper quadrant
Abdominal pain; left upper quadrant
Abdominal pain; right lower quadrant
Abdominal pain; left lower quadrant
Abdominal pain; periumbilic
Abdominal pain; epigastric
Abdominal pain; generalized
Abdominal pain; other specified site
Abdominal or pelvic swelling, mass or lump
Abdominal or pelvic swelling, mass or lump; unspecified
Abdominal or pelvic swelling, mass or lump; periumbilic
Abdominal or pelvic swelling, mass or lump; epigastric
Ascites ‐ fluid in peritoneal cavity; other specified site
Abdominal tenderness
Abdominal tenderness; periumbilic

78966
78960
7899
5361
5369
7830
7831
7832
7873
7879
78791
7880
7881
7883
78840
78841
78842
78843

Abdominal tenderness; epigastric
Abdominal tenderness; unspecified
Other symptoms involving abdomen and pelvis
Acute dilatation of stomach
Unspecified functional disorder of stomach
Anorexia (loss of appetite)
Abnormal weight gain
Abnormal weight loss
Flatulence, eructation & gas pain
Other symptoms involving digestive system
Diarrhea
Renal colic
Dysuria
Urinary incontinence
Frequency of urination & polyuria
Urinary frequency
Polyuria
Nocturia
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Table 2: Summary of Match Criteria

Match Criteria for case controls
Age at first symptom (years)
20‐29
30‐39
40‐49
50‐59
60‐69
>65
Total
First Symptom
abdom_pelvis
bladder
digestive
pain
Total
Observation Months
6‐12 mo.
12‐24 mo.
25‐36 mo.
37‐48 mo.
49‐60 mo.
61‐70 mo.
Total

case( n=789) /
control (n=789)

%

50
230
414
486
186
212
1578

3%
15%
26%
31%
12%
13%
100%

858
226
232
262
1578

54%
14%
15%
17%
100%

414
520
332
156
122
34
1578

26%
33%
21%
10%
8%
2%
100%

63

Table 3: Individual symptoms experienced in women with ovarian cancer
(case) and women without cancer (controls)

Symptom
Digestive
Bladder
Pain
Abdom_Pelvis

case
control
%
Total
(n=789) % Case (n=789) Control Women
281
36%
297 38%
578
226
29%
258 33%
484
464
59%
376 48%
840
725
92%
696 88% 1421

%
Total Odds ratio (95% CI) P Value
37% .87 (.676 to 1.13)
0.298
31% .72 (.54 to .96)
0.024
53% 1.75 (1.39 to 2.19)
<.001
90% 1.66 (1.14 to 2.41)
0.008

Table 4: Combination symptoms experienced in women with ovarian cancer
(case) and women without cancer (controls)

Combination Visits
AbP+B
AbP+B+D
AbP+B+D+P
AbP+D
D+B
P+AbP
P+AbP+B
P+AbP+D
P+B
P+D
Total Women Experiencing
Combination of Symptoms

case
control
%
Total %
(n=789) % Case (n=789) Control Visits Total Odds ratio (95% CI) P Value
55
9%
73
12%
128 11% .72 (.49 to 1.04)
0.09
22
4%
40
7%
62 5% .53 (.31 to .90)
0.20
45
7%
34
6%
79 6% 1.37 (.85 to 2.19)
0.19
89
14%
120
20%
209 17% .66 (.48 to .92)
0.01
13
2%
12
2%
25 2% 1.08 (.5 to 2.37)
0.84
206
33%
153
26%
359 30% 1.54 (1.19 to 1.99)
0.001
73
12%
63
11%
136 11% 1.85 (.83 to 1.70)
0.36
99
16%
67
11%
166 14% 1.58 (1.13 to 2.22)
0.008
10
2%
22
4%
32 3% .40 (.18 to .91)
0.028
9
1%
11
2%
20 2% .78 (.289 to 2.09)
0.62
621

100%

595

100%

1,216 100%
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Figures 1 – 4: Frequency of Symptom Visits in women with ovarian cancer
(cases) and women without cancer (controls)
Figure 1 – Summary of Digestive Visits
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Figure 2 – Summary of Bladder Visits
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Figure 3 – Summary of Pain Visits
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Figure 4 – Summary of Abdomen - Pelvis Visits
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